RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells.
- DOI
- 10.1097/cad.0000000000001500
- Published
- 2023 Apr 1
- Container
- Anti-cancer drugs
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/cad.0000000000001500,
title = {RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells.},
author = {Patel H and Mishra R and Wier A and Mokhtarpour N and Merino EJ and Garrett JT},
year = {2023},
journal = {Anti-cancer drugs},
doi = {10.1097/cad.0000000000001500},
url = {https://doi.org/10.1097/cad.0000000000001500}
}RIS
TY - JOUR TI - RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells. AU - Patel H AU - Mishra R AU - Wier A AU - Mokhtarpour N AU - Merino EJ AU - Garrett JT PY - 2023 JO - Anti-cancer drugs DO - 10.1097/cad.0000000000001500 UR - https://doi.org/10.1097/cad.0000000000001500 ER -
APA
H, P., R, M., A, W., N, M., EJ, M., & JT, G. (2023). RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells.. Anti-cancer drugs. https://doi.org/10.1097/cad.0000000000001500
Source records
- pubmed · retrieved 2026-09-27T11:06:27.140Z
- europe-pmc · retrieved 2026-09-27T11:06:27.144Z